The Gates Foundation has awarded Evaxion A/S (NASDAQ:EVAX) a grant to use its exclusive AI-Immunology™ technology to develop a new polio vaccine.
Person in a lab coat looking through a microscope examining cells for research into a new vaccine.
The funds will be used to support research into identifying and combining antigens to create a new vaccine design that does not utilize live viruses. By developing a safer and more effective substitute for conventional polio vaccines, this project seeks to mitigate the persistent risks of polio reappearance without placing a financial strain on Evaxion A/S.
Polio is still a problem in the world today, even after decades of immunization attempts. Existing vaccinations use live or inactivated virus constructions, which can be dangerous in some situations. The clinically validated AI-Immunology™ platform from Evaxion A/S will be used to find new antigen combinations for safer vaccine formulation.
The Gates Foundation award allows for strategic R&D advancement without affecting operating expenses, CEO Christian Kanstrup stressed.
Evaxion A/S’s contribution to the global eradication of infectious diseases through the use of next-generation vaccine technology is strengthened by this project.
READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025.
Disclosure. None.
